Results 11 to 20 of about 1,991 (194)

Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy [PDF]

New England Journal of Medicine
BACKGROUND: Mavacamten is approved to treat adults with symptomatic obstructive hypertrophic cardiomyopathy (HCM). However, its effects in nonobstructive HCM remain uncertain. METHODS: We conducted a phase 3, international, double-blind, placebo-controlled, clinical trial to determine whether mavacamten improves functional capacity and patient-reported
Milind Y Desai, Perry M Elliott, Benjamin Meder   +2 more
exaly   +8 more sources

Transcriptional and functional effects of mavacamten in multiple porcine and human models with hypertrophic cardiomyopathy [PDF]

British Journal of Pharmacology, Volume 183, Issue 5, Page 1122-1139, March 2026.
Background and Purpose: Mavacamten (MAVA) is a novel small molecule inhibitor of cardiac myosin, mitigating cardiomyocyte hypercontractility in patients with hypertrophic obstructive cardiomyopathy (HOCM).
Agyapong, Wilson, Beetz, Oliver, Bentele, Marco, Chatterjee, Shambhabi, Cipriano, Giuseppe, Derda, Anselm A., Gietz, Anika, Haas, Jonas A., Hunkler, Hannah J., Jürgens, Bjarne, Kiselev, Elisa, Liu, Junqing, Menge, Kaja S., Mohr, Elisa, Neumüller, Susanne, Pfanne, Angelika, Pflaum, Michael, Psaras, Yiangos, Salman, Jawad, Sonnenschein, Kristina, Specht, Jonas, Toepfer, Christopher, Waleczek, Florian J. G., Wiegmann, Bettina   +23 more
core   +3 more sources

Precision Negative Inotropy: The Rise of Cardiac Myosin Inhibitors in HCM [PDF]

Journal of Education, Health and Sport
Background: Hypertrophic cardiomyopathy (HCM) is the most common heritable cardiomyopathy, marked by left-ventricular hypertrophy, dynamic outflow obstruction in many patients, diastolic dysfunction, and elevated risks of atrial fibrillation and heart ...
Katarzyna Skibicka, Tomasz Skibicki, Weronika Wesołowska, Robert Bujak   +3 more
doaj   +3 more sources

Hemodynamic and symptomatic response in hypertrophic obstructive cardiomyopathy patients on myosin inhibitor therapy [PDF]

Frontiers in Cardiovascular Medicine
AimsTo provide real-world data on the symptomatic and hemodynamic response of the myosin inhibitor mavacamten in patients with hypertrophic obstructive cardiomyopathy (HOCM).MethodsPatients with HOCM up-titrated to their final mavacamten dose were ...
Katharina Seuthe, Athanasios Feidakis, Richard Nies, Monique Brüwer, Lenhard Pennig, Kenan Kaya, Henrik ten Freyhaus, Stephan Baldus, Roman Pfister   +8 more
doaj   +2 more sources

Pharmacogenetic testing to broaden patient eligibility for mavacamten [PDF]

European Heart Journal - Cardiovascular Pharmacotherapy
The European Medicines Agency (EMA) approved mavacamten in June 2023 for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM).1,2 Clinical trials have demonstrated its efficacy in improving exercise capacity, reducing the left ventricular outflow tract (LVOT) gradient, and alleviating symptoms, and decreases the need for invasive
Lorenz Van der Linden, Lucas Van Aelst, Iacopo Olivotto   +2 more
openaire   +5 more sources

Review of Mavacamten for Obstructive Hypertrophic Cardiomyopathy and Future Directions

Drug Design, Development and Therapy, 2023
Tiffany Dong,* Ben Alencherry,* Susan Ospina, Milind Y Desai Section of Cardiovascular Imaging, Heart, Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, OH, USA*These authors contributed equally to this workCorrespondence: Milind ...
Tiffany Dong, Ben Alencherry, Milind Y Desai   +2 more
exaly   +2 more sources

Mavacamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy [PDF]

JACC: Heart Failure
http://dx.doi.org/10.13039/100002491 Bristol-Myers ...
Florian Rader, Artur Oręziak, Lubna Choudhury, Sara Saberi, David Fermin, Matthew T. Wheeler, Theodore P. Abraham, Pablo Garcia-Pavia, Donna R. Zwas, Ahmad Masri, Anjali Owens, Sheila M. Hegde, Tim Seidler, Shawna Fox, Ganesh Balaratnam, Amy J. Sehnert, Iacopo Olivotto   +16 more
core   +7 more sources

Myosin folding boosts solubility in cardiac muscle sarcomeres [PDF]

JCI Insight
The polymerization of myosin molecules into thick filaments in muscle sarcomeres is essential for cardiac contractility, with the attenuation of interactions between the heads of myosin molecules within the filaments being proposed to result in ...
Colleen M. Kelly, Jody L. Martin, Michael J. Previs   +2 more
doaj   +2 more sources

Mavacamten as an Effective Treatment for HCM With Latent Exercise-Induced Obstruction: A Case Report. [PDF]

Case Rep Cardiol
Background Hypertrophic cardiomyopathy (HCM) is a myocardial disorder characterized by hypertrophy of the left ventricle that can lead to significant symptoms, particularly with exercise. For patients with HCM who demonstrate obstructive physiology, the first‐in‐class targeted cardiac specific myosin inhibitor, mavacamten, has been found to reduce the ...
Murthy N, Diep B, Evans J, Abramov D, Tran D.   +4 more
europepmc   +2 more sources

Low-Dose Mavacamten Initiation in Obstructive Hypertrophic Cardiomyopathy: A Real-World Study in China. [PDF]

Cardiovasc Ther
Aims To evaluate the real‐world efficacy and safety of low‐dose (2.5 mg) mavacamten initiation in Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Methods and Results This single‐center observational study (Zhongshan Hospital, China; Oct 2024–Apr 2025) enrolled 72 symptomatic oHCM patients (NYHA II/III, LVEF ≥ 55 ...
Yang W, Shi H, Chang RS, Zhang Y, Jixiang A, Wu C, Qian J, Ge J, Zhang S.   +8 more
europepmc   +2 more sources